The Zacks Analyst Blog Highlights Moodys, Stryker and CBRE

22.10.25 15:20 Uhr

Werte in diesem Artikel
Aktien

415,50 EUR 0,20 EUR 0,05%

337,10 EUR 10,80 EUR 3,31%

Indizes

6.699,4 PKT -36,0 PKT -0,53%

For Immediate ReleaseChicago, IL – October 22, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Moody’s Corp. MCO, Stryker Corp. SYK and CBRE Group Inc. CBRE.Here are highlights from Tuesday’s Analyst Blog:Buy 3 Wide-Moat Stocks to Enhance Your Portfolio Returns in Q4The wide moat strategy involves investing in companies that not only lead their industries but are also strategically fortified to maintain dominance in the future. The business models of these companies possess durable competitive advantages that shield them from competitors. This strategy isn't just about recording short-term gains, but securing a portfolio of stocks that can weather economic storms and deliver stable and predictable returns.This investment strategy focuses on companies with unique strengths such as brand recognition, patent protection, proprietary technology and network effects. These moats ensure long-term profitability and market leadership, making the companies resilient in volatile markets.Here we recommend three Wide Moat stocks with a favorable Zacks Rank. These stocks are: Moody's Corp., Stryker Corp. and CBRE Group Inc.. Each of our picks carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.Moody's Corp.Moody's dominant position in the credit rating industry, along with opportunistic acquisitions and restructuring efforts to diversify revenues and footprint, supports top-line expansion. A solid rebound in bond issuance volume is expected to drive MCO's growth in future. A strong balance sheet position and earnings strength are likely to keep MCO's capital distributions sustainable.Moody's has been meaningfully growing through strategic acquisitions, increasing scale and cross-selling opportunities across products and vertical markets. In August 2025, MCO announced its plans to secure a majority equity ownership in Middle East Rating & Investors Service (MERIS).In June 2025, MCO fully acquired ICR Chile, strengthening its presence in Latin America's domestic credit markets (in 2019, the company had acquired a minority stake in ICR Chile). In 2024, MCO announced the acquisition of Numerated Growth Technologies and a 100% stake in GCR to deepen its presence in Africa's credit market.Moody's has an expected revenue and earnings growth rate of 8.2% and 15.7%, respectively, for the current quarter. The Zacks Consensus Estimate for current-quarter earnings has improved 0.3% in the past seven days.Stryker Corp.Stryker is delivering robust growth, supported by diversified businesses across Orthopaedics and MedSurg & Neurotechnology, with innovation-led momentum from Mako SmartRobotics, trauma solutions, and emergency care platforms. SYK's strong first-half 2025 led management to raise full-year organic growth guidance to 9.5–10%.SYK's recent product launches—LIFEPAK 35, Pangea plating, Insignia hip—strengthen the product cycle of SYK. At the same time, acquisitions like Inari broaden SYK's vascular footprint. Margin expansion is fueled by pricing, mix, and cost efficiency.Stryker has an expected revenue and earnings growth rate of 9.8% and 9.5%, respectively, for the current quarter. The Zacks Consensus Estimate for current-quarter earnings has improved 1.6% in the past 90 days.CBRE Group Inc.CBRE Group is well-positioned to gain from its wide range of real estate products and services. CBRE has opted for a better-balanced and more resilient business model in recent years and continues to gain from its diversification efforts.CBRE's outsourcing business remains healthy, and its pipeline is likely to remain elevated, offering scope for growth. Strategic buyouts and technology investments are expected to drive CBRE's performance. We expect total revenues to increase 11.1% and 7% year over year in 2025 and 2026, respectively.CBRE Group has an expected revenue and earnings growth rate of 9.8% and 15.1%, respectively, for the current quarter. The Zacks Consensus Estimate for current-quarter earnings has improved 0.4% in the past 30 days.Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.Today you can access their live picks without cost or obligation.See Stocks Free >>Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.com                                      https://www.zacks.com                                                 Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.See "2nd Wave" AI stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Moody's Corporation (MCO): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report CBRE Group, Inc. (CBRE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Moodys und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Moodys

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Moodys

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Stryker Corp.

Wer­bung

Analysen zu Stryker Corp.

DatumRatingAnalyst
30.01.2019Stryker BuyCanaccord Adams
03.01.2019Stryker BuyDeutsche Bank AG
16.10.2018Stryker OverweightBarclays Capital
16.08.2018Stryker BuyBTIG Research
27.04.2018Stryker BuyCanaccord Adams
DatumRatingAnalyst
30.01.2019Stryker BuyCanaccord Adams
03.01.2019Stryker BuyDeutsche Bank AG
16.10.2018Stryker OverweightBarclays Capital
16.08.2018Stryker BuyBTIG Research
27.04.2018Stryker BuyCanaccord Adams
DatumRatingAnalyst
05.01.2018Stryker NeutralCantor Fitzgerald
25.08.2017Stryker HoldNeedham & Company, LLC
30.06.2017Stryker NeutralCantor Fitzgerald
06.01.2017Stryker UnderperformNeedham & Company, LLC
13.04.2016Stryker NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
27.10.2017Stryker UnderweightBarclays Capital
11.04.2016Stryker UnderweightBarclays Capital
18.12.2015Stryker UnderperformBMO Capital Markets
02.04.2015Stryker UnderweightBarclays Capital
03.05.2010Stryker "underweight"Barclays Capital

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Stryker Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen